Mometasone furoate works by binding to glucocorticoid receptors inside nasal cells. This binding triggers a cascade of intracellular events that reduce inflammation. Specifically, it inhibits the production of inflammatory mediators like leukotrienes, prostaglandins, and cytokines, key players in allergic rhinitis and other nasal inflammations.
Inhibition of Inflammatory Cell Activity
The drug also reduces the recruitment and activation of inflammatory cells, such as eosinophils, mast cells, and lymphocytes, to the nasal mucosa. Fewer inflammatory cells mean less inflammation and a subsequent reduction in symptoms like sneezing, runny nose, and congestion. This targeted approach minimizes systemic effects while effectively managing nasal inflammation.
Long-Term Effects and Receptor Binding
Mometasone furoate’s high affinity for glucocorticoid receptors ensures prolonged activity. This strong binding means a smaller dose provides sustained relief, minimizing the risk of side effects associated with higher doses of corticosteroids. The effects on inflammation are cumulative, meaning that consistent use leads to a gradual reduction of overall nasal inflammation.
